Dupilumab undergoing trials to treat nasal polyps
Better treatment for nasal polyps may be on the way. An early trial of a drug published by a research team led by Dr. Claus Bachert of Belgium suggests potential benefit in reducing resistant nasal polyp burden.
Chronic sinusitis affects around 15% of the population and can lead to recurrent sinus infections. Several treatment options are currently available, including medicines, in-office procedures, and surgery.
Dupilumab is a medicine that is injected in the skin and has shown benefit in asthma and atopic dermatitis (allergy rash). This new study investigated patients with chronic sinusitis with nasal polyps refractory to nasal steroid sprays. Researches followed 60 subjects randomized to treatment groups for 16 weeks. Statistically significant improvements were seen in CT scan scores, sinus-related quality of life, and smelling function.
Adverse effects were mild, including inflammation of the nasopharynx (back of the nose) (47% v. 33% in placebo group), injection site reactions (40% v. 7%), and headache (20% v. 17%).
The authors recommended further larger studies.
View Source Here.
To see Dr. Thomas S. Higgins, Jr., MD, MSPH, a fellowship-trained Rhinologist (Sinus Specialist) experienced with Nasal Polyps, click below
or call (502) 894-8441.
Welcome to Nose and Sinus News on www.higgins-sinus.com, where we post news, highlights, and interesting stories about nose and sinus disease! Check back often!